CINGULATE INC (CING) Stock Overview
NASDAQ:CING - US17248W3034 - Common Stock
CING Key Statistics, Chart & Performance
The current stock price of CING is 4.3 USD. In the past month the price decreased by -16.67%. In the past year, price decreased by -45.5%.
CING Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 45.57 | 696.62B | ||
| JNJ | JOHNSON & JOHNSON | 17.65 | 425.05B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.03 | 248.19B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 14.19 | 245.90B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14.31 | 245.16B | ||
| MRK | MERCK & CO. INC. | 11.04 | 212.29B | ||
| PFE | PFIZER INC | 7.35 | 141.68B | ||
| SNY | SANOFI-ADR | 11.38 | 122.68B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.01 | 96.09B | ||
| GSK | GSK PLC-SPON ADR | 8.81 | 80.29B | ||
| ZTS | ZOETIS INC | 24.89 | 68.60B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 49.6 | 46.99B |
Related stock screener links
About CING
Company Profile
Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using Precision Timed Release, drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The company is headquartered in Kansas City, Kansas and currently employs 13 full-time employees. The company went IPO on 2021-10-07. The firm is focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles. The company focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The firm is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). The Company’s CTx-1301 and CTx-1302 are being developed for the treatment of ADHD in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+). In addition, the Company has a third product to treat anxiety, CTx-2103, in a formulation stage. Its CTx-1301, CTx-1302 and CTx-2103 drug candidates contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form.
Company Info
CINGULATE INC
1901 W. 47Th Place
Kansas City KANSAS US
Employees: 13
Phone: 19139422300
CINGULATE INC / CING FAQ
What is the stock price of CINGULATE INC today?
The current stock price of CING is 4.3 USD. The price increased by 2.26% in the last trading session.
What is the ticker symbol for CINGULATE INC stock?
The exchange symbol of CINGULATE INC is CING and it is listed on the Nasdaq exchange.
On which exchange is CING stock listed?
CING stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CINGULATE INC stock?
10 analysts have analysed CING and the average price target is 29.38 USD. This implies a price increase of 583.16% is expected in the next year compared to the current price of 4.3. Check the CINGULATE INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CINGULATE INC worth?
CINGULATE INC (CING) has a market capitalization of 22.14M USD. This makes CING a Nano Cap stock.
How many employees does CINGULATE INC have?
CINGULATE INC (CING) currently has 13 employees.
What are the support and resistance levels for CINGULATE INC (CING) stock?
CINGULATE INC (CING) has a support level at 4.07 and a resistance level at 4.31. Check the full technical report for a detailed analysis of CING support and resistance levels.
Should I buy CINGULATE INC (CING) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CING, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CING, evaluating the profitability, health, valuation and growth aspects
- CINGULATE INC (CING) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CINGULATE INC (CING) Sales and EPS estimates to see what analysts future expectations are.
- CINGULATE INC (CING) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CINGULATE INC (CING) Insider and Institutional Ownership to learn about the owners and their transactions.
- CINGULATE INC (CING) Stock Chart to make your own analysis
- CINGULATE INC (CING) Latest news and press-releases to stay up to date.
Does CINGULATE INC (CING) stock pay dividends?
CING does not pay a dividend.
What is the Price/Earnings (PE) ratio of CINGULATE INC (CING)?
CINGULATE INC (CING) does not have a PE ratio as the earnings reported over the last twelve months were negative (-18.52).
What is the Short Interest ratio of CINGULATE INC (CING) stock?
The outstanding short interest for CINGULATE INC (CING) is 4.47% of its float. Check the ownership tab for more information on the CING short interest.
CING Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to CING. When comparing the yearly performance of all stocks, CING is a bad performer in the overall market: 88.65% of all stocks are doing better.
CING Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to CING. Both the profitability and financial health of CING have multiple concerns.
CING Financial Highlights
Over the last trailing twelve months CING reported a non-GAAP Earnings per Share(EPS) of -18.52. The EPS increased by 95.19% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -133.31% | ||
| ROE | -325.75% | ||
| Debt/Equity | 0.93 |
CING Forecast & Estimates
10 analysts have analysed CING and the average price target is 29.38 USD. This implies a price increase of 583.16% is expected in the next year compared to the current price of 4.3.